Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1974-1984

  O'Reilly, S ^a   Grochow, L B ^a   Donehower, R C ^a   Chen, T L ^a   Bowling, K ^a   Hartman, N R ^a   Struck, R F ^a   Rowinsky, E K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; PENCLOMEDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TOLERANCE; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UROGENITAL TRACT CANCER;

EID: 0030906399     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1974     Document Type: Article

References (32)

1. Plowman J, Harrison SD Jr, Dykes DJ, et al: Preclinical antitumor activity of an alpha picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res 49:1909-1915, 1989
2. Harrison SD Jr, Plowman J, Dykes DJ, et al: Preclinical antitumor activity of penclomedine in mice: Cross resistance, schedule dependance, and oral activity against tumor xenografts in brain. Cancer Res 51:1979-1983, 1991
3. Black PML: Brain Tumors. N Eng J Med 324:1471-1476, 1991
4. Reid JM, Mathieson DA, Benson LM, et al: Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]. Cancer Res 52:2830-2834, 1992
5. Hartman NR, Leo K, Brewer TG, et al: Metabolism of penclomedine by the isolated perfused rat liver. Proc Am Assoc Cancer Res 37:394, 1996 (abstr 2692)
6. Hartman NR, O'Reilly S, Rowinsky EK, et al: Murine and human in vivo metabolism of penclomedine. Clin Cancer Res 2:953-962, 1996
7. 14C-penclomedine in rats. Clin Cancer Res 2:541-548, 1996
8. O'Reilly S, Grochow L, Donehower R, et al: Phase I, pharmacologic and preclinical studies of the novel alkylating agent penclomedine in patients with solid tumors. Ann Oncol 7:99, 1996 (abstr 347; suppl 1)
9. Penclomedine. Investigators Brochure. Bethesda, MD, National Cancer Institute, 1992
10. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state," a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
11. Folstein MF, Fetting JH, Lobo A, et al: Cognitive assessment of cancer patients. Cancer 53:2250-2255, 1984 (suppl)
12. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
13. Metzler CM: Extended least squares for pharmacokinetic models. J Pharm Sci 76:565-571, 1987
14. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
15. Chiou WL: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokin Biopharm 6:539-546, 1978
16. Charter MK: The estimate of moments: A technical note. J Pharmacokin Biopharm 17:203-208, 1989
17. Altman DG: Practical Statistics for Medical Research. London, United Kingdom, Chapman and Hall, 1991
18. LoRusso P, Foster BJ, Poplin E, et al: Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1:1487-1493, 1995
19. Agresti A: Categorical Data Analysis. New York, NY, Wiley, 1990
20. Takvorian T, Parker LM, Hochberg FH, et al: Autologous bone marrow transplantation: Host effects of high dose BCNU. J Clin Oncol 1:610-620, 1983
21. Morley A, Trainor K, Blake J: A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 45:681-688, 1974
22. Tew K, Colvin OM, Chabner BA: Alkylating agents, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott Raven, 1996, pp 297-332
23. Berlin J, Stewart J, Tutsch K, et al: Phase I trial of penclomedine using a novel escalation scheme. Proc Am Soc Clin Oncol 14:478, 1995 (abstr 1553)
24. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
25. Jodrell DI, Bowman A, Stewart M, et al: A clinical phase I and pharmacokinetic study of penclomedine, a synthetic alpha picoloine derivative. Ann Oncol 7:99, 1996 (abstr 346; Suppl 1)
26. Castellanos AM, Fields WS: Grading of neurotoxicity in cancer therapy. J Clin Oncol 4:1277-1278, 1986 (letter)
27. O'Reilly S, O'Hearn E, Rowinsky E, et al: Neuroanatomic studies of the cerebellar toxicity of penclomedine. Proc Am Assoc Cancer Res 37:374, 1996 (abstr 2555)
28. O'Hearn E, Moliver ME: Degeneration of Purkinje cells in parasagittal zones in the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55:303-310, 1993
29. Ross CA, Bredt D, Snyder SH: Messenger molecules in the cerebellum. Trends Neurol Sci 13:216-222, 1990
30. Neben S, Hellman S, Montgomery M, et al: Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 21:156-162, 1993
31. Fetell MR, Grossman SA, Balmaceda C, et al: Clinical and pharmacologic study of preirradiation Taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiforme. Proc Am Soc Clin Oncol 13:179, 1994 (abstr 504)
32. Bagniewski PG, Reid JM, Ames MM, et al: Increased etoposide clearance in patients with glioma may be associated with concurrent glucocorticoid or anticonvulsant treatment. Proc Am Assoc Cancer Res 37:179, 1996 (abstr 1224)